Friday, January 8, 2010, 10:23PM AEST - The Australian Stockmarket is closed.
To create a watchlist or portfolio of shares, Register

AP Pharma Inc. (APPA)

8:00AM AEST: 1.41 USD   0.00 (0.00%)  
 MORE ON APPA 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 A.P. Pharma, Inc. (NCM:APPA) Delayed quote dataEdit
Last Trade:1.41 USD
Trade Time: 8:00AM AEST
Change: 0.00 (0.00%)
Prev Close:1.41
Open:N/A
Bid:0.90 x 100
Ask:N/A
1y Target Est:2.50
Day's Range:N/A - N/A
52wk Range:0.38 - 1.40
Volume:0
Avg Vol (3m):94,133.3
Market Cap:55.52M
P/E (ttm):N/A
EPS (ttm):-0.39
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add APPA to Portfolio   Download Data

 HEADLINES 
AP PHARMA INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
EDGAR Online (Wed, Nov 25)
A.P. Pharma Receives Notice of Compliance with Nasdaq Continued Listing Requirements
Business Wire (Mon, Nov 23)
AP PHARMA INC /DE/ Financials
EDGAR Online Financials (Sat, Nov 21)
AP PHARMA INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Tue, Nov 17)
AP PHARMA INC /DE/ Files SEC form 10-Q, Quarterly Report
EDGAR Online (Tue, Nov 17)
A.P. Pharma Q3 loss narrows to $1.2M
at bizjournals.com (Tue, Nov 17)
A.P. Pharma Reports Third Quarter 2009 Financial Results
Business Wire (Mon, Nov 16)
AP PHARMA INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
EDGAR Online (Thu, Oct 29)
A.P. Pharma to Transfer to Nasdaq Capital Market
Business Wire (Wed, Oct 28)
AP PHARMA INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securi
EDGAR Online (Fri, Oct 23)
More Headlines for APPA...

 ANALYST 
EPS Est (next year) (Dec-09) :N/A
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
A.P. Pharma, Inc., a specialty pharmaceutical company, engages in developing pharmaceutical products using its proprietary Biochronomer polymer-based drug delivery technology.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices